Details

Autor(en) / Beteiligte

• McPherson, Tristan D.
• Ghinai, Isaac
• Binder, Alison M.
• Freeman, Brandi D.
• Hoskin Snelling, Chantel
• Hunter, Jennifer C.
• Anderson, Kristin M.
• Davenport, Polly
• Rudd, Deborah L.
• Zafer, Mujeeb
• Christiansen, Demian
• Joshi, Kiran
• Rubin, Rachel
• Black, Stephanie R.
• Fricchione, Marielle J.
• Pacilli, Massimo
• Walblay, Kelly A.
• Korpics, Jacqueline
• Moeller, Darcie
• Quartey-Kumapley, Pearl
• Wang, Chen
• Charles, E. Matt
• Kauerauf, Judy
• Patel, Megan T.
• Disari, Vishal S.
• Fischer, Marc
• Jacobs, Max W.
• Lester, Sandra N.
• Midgley, Claire M.
• Rasheed, Mohammed Ata Ur
• Reese, Heather E.
• Verani, Jennifer R.
• Wallace, Megan
• Watson, John T.
• Thornburg, Natalie J.
• Layden, Jennifer E.
• Kirking, Hannah L.

Titel

Lack of Serologic Evidence of Infection Among Health Care Personnel and Other Contacts of First 2 Confirmed Patients With COVID-19 in Illinois, 2020

Ist Teil von

• Public health reports (1974), 2021-01, Vol.136 (1), p.88-96

Ort / Verlag

Los Angeles, CA: SAGE Publications

Erscheinungsjahr

2021

Link zum Volltext

Quelle

PAIS Index

Beschreibungen/Notizen

• Objectives Widespread global transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19), continues. Many questions remain about asymptomatic or atypical infections and transmission dynamics. We used comprehensive contact tracing of the first 2 confirmed patients in Illinois with COVID-19 and serologic SARS-CoV-2 antibody testing to determine whether contacts had evidence of undetected COVID-19. Methods Contacts were eligible for serologic follow-up if previously tested for COVID-19 during an initial investigation or had greater-risk exposures. Contacts completed a standardized questionnaire during the initial investigation. We classified exposure risk as high, medium, or low based on interactions with 2 index patients and use of personal protective equipment (PPE). Serologic testing used a SARS-CoV-2 spike enzyme-linked immunosorbent assay on serum specimens collected from participants approximately 6 weeks after initial exposure to either index patient. The 2 index patients provided serum specimens throughout their illness. We collected data on demographic, exposure, and epidemiologic characteristics. Results Of 347 contacts, 110 were eligible for serologic follow-up; 59 (17% of all contacts) enrolled. Of these, 53 (90%) were health care personnel and 6 (10%) were community contacts. Seventeen (29%) reported high-risk exposures, 15 (25%) medium-risk, and 27 (46%) low-risk. No participant had evidence of SARS-CoV-2 antibodies. The 2 index patients had antibodies detected at dilutions >1:6400 within 4 weeks after symptom onset. Conclusions In serologic follow-up of the first 2 known patients in Illinois with COVID-19, we found no secondary transmission among tested contacts. Lack of seroconversion among these contacts adds to our understanding of conditions (ie, use of PPE) under which SARS-CoV-2 infections might not result in transmission and demonstrates that SARS-CoV-2 antibody testing is a useful tool to verify epidemiologic findings.